Cite Score:
0.89
CITE SCORE SCOPUS

Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer

AUTHORS

Hamid Saeidi Saedi 1 , * , M Seilanian Toosi 2 , M Mirsadraei 3 , S Roodbari 4

1 Assistant Professor of radiation oncology, Department of Oncology, Omid Hospital, Iran

2 Assistant Professor of radiation oncologist, Department of Oncology, Omid Hospital, Cancer Research Center, Iran

3 Assistant of radiation oncology, Department of oncology department of Omid Hospital, Cancer Research Center, Iran

4 Assistant of General Surgery, Department of Oncology, Omid Hospital, Cancer Research Center, Iran

How to Cite: Saeidi Saedi H , Seilanian Toosi M, Mirsadraei M, Roodbari S. Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer , Int J Cancer Manag. 2008 ; 1(3):e80475.

ARTICLE INFORMATION

International Journal of Cancer Management: 1 (3); e80475
Published Online: September 30, 2008
Article Type: Research Article
Received: September 30, 2008
Accepted: September 30, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Purpose: Metastatic breast cancer has remained as an incurable disease. The main objectives of treatments include alleviating of symptoms, delaying disease progression and increasing survival without any adverse effect on the quality of life. The main purpose of this study was to investigate the effects of some clinocopathological factors on the survival of patients with metastatic breast carcinoma in our institute.

Patients and Methods: In this retrospective cohort study, we reviewed the files of patients who were metastatic at presentation or became metastatic during follow-up and were referred to oncology department of Omid Hospital affiliated to Mashhad University of Medical Sciences from 1997 to 2007. The information regarding clinicopathological characteristics were recorded. The first line chemotherapy regimen was as follows: 79 CAF (cyclophosphamide, doxurobicine, 5FU), 25 CMF (cyclophosphamide, methotrexate, 5FU) and 11 Taxene based; AT (doxorubicin, paclitaxol) or TAC (taxene, doxurobicine, cyclophosphamide).

Results: 115 patients with a median age of 45 (range, 25-78) were investigated. The median follow-up time for all patients from diagnosis was 21 months (range, 5- 74 months) and from metastatic manifestation was 12 months (5-36 months). The sites of recurrence or metastasis were as follows: 18 (15.7%) local recurrence, 23(20%) bone and 74 (64.3%) visceral metastases. The median and 2- year overall survival for all patients with metastatic disease were 15 months and 44.6% ± 6% respectively. Patients with bone metastasis had a significantly better overall survival compared to those with visceral metastasis. (74.2%vs.36.1%, P= 0.04) Among those patients who were non-metastatic at the time of referral, the time left to metastasis had a significant effect on the overall survival from metastasis manifestation. In comparison with premenopausal patients, the overall survival was relatively better in postmenopausal cases. (59.4% vs. 38.5%, P=0.1)

Conclusion: In our study, disease free survival (DFS) was the most important factor for overall survival in patients with metastatic breast cancer. The patients with longer DFS (>18month) had better overall survival. Overall the patients with bone metastasis had better survival than visceral metastasis.

Keywords

prognostic factors metastatic breast cancer disease free survival

© 2008, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

Full text is available in PDF.

COMMENTS

LEAVE A COMMENT HERE: